Completion↦Safety↦Clinical Study Report↦Procedures
Was betrifft es? Warum ist das wichtig?
A Clinical Study Report (CSR) is a summary describing the set-up, conduct, safety, and results of a study.
The CSR is also referred to:
- In ICH GCP as a “Clinical trial / Study report” (CSR)
- In ClinO-MD as a Clinical Investigation Report (CIR)
- As a Final Study Report (FSR)
The aim of a CSR/CIR/FSR is to provide, among others, a summary regarding:
- Study set-up (e.g. study design, study blinding, study population, treatment, outcome/endpoints)
- Study quality assurance (e.g. study defined Critical to Quality (CtoQ) factors, identified risks threatening CtoQ and the implementation of risk control measures)
- Changes to study conduct (e.g. participant recruitment / drop-outs, non-compliances such as protocol deviations)
- Safety Evaluation (e.g. treatment exposure, summary of Adverse Events)
- Statistical analysis (e.g. sample size calculation, analysis method, SAP)
- Efficacy evaluation and results
- Discussion and overall study conclusion
Mehr
he report has a “safety evaluation” section, where study safety data is evaluated and described on three levels:
- Level 1: Extent of exposure: such as dose administered, duration of treatment, number of participants treated in the study (e.g. extent of exposure helps to decide the degree to which safety can be assessed from the study)
- Level 2: Most common adverse events (Investigational Medicinal Product (IMP) = AE, Investigational Medical Device (IMD = ADE): including changes in laboratory test parameters
- Level 3: Serious adverse events (IMP = SAE / SADR, IMD = SDE): a description of each death, serious adverse event, including the occurrence of other significant adverse events during study conduct
Was muss ich befolgen?
As a Site-INV, same procedures apply as defined for the annual safety report (e.g. the submission of safety data to the SP-INV)
As a SP-INV of a:
- ClinO study, prepare CSR based on specifications provided in ICH E3 (structure and content of CSR)
- ClinO-MD study, prepare a CIR based on Annex D in ISO 14155 (set-up and results of the clinical investigation)
Irrespective whether a study was completed or prematurely terminated, submit a CSR/CIR to:
- The Ethics Committee (EC) via BASEC portal
- Swissmedic, for risk-category B and C studies, via Swissmedic portal
Publication responsibilities:
- Study results must be published irrespective whether they are positive, nonconclusive, or negative. This will help guide future research, device development and medical treatment.
- To ensure research transparency, publish results in publicly accessible databases (e.g. study registries)
- As applicable, enter results in a scientific publication
- As applicable, provide study participants with study results
Mehr
A CSR/CIR is only written after:
- The completion of the monitoring close-out visit
- The Lock the study database and data export for data analysis
- Completion of data analyses (e.g. according to SAP) and presentation of study results. In the event of a blinded study, unblinding only takes place after data analysis and the documentation of study results
Wo kann ich Hilfe anfordern?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
External Links
Swissethics – see in particular
- Templates and checklists / Notifications
- Study completion / discontinuation
Swissmedic – see in particular information sheet
- BW101_10_003e_AA Instruction for reporting during the course of a study
References
ICH GCP E6(R3) – see in particular guideline
- Glossary: definition of a CSR
- 3.17.2 Clinical trial / Study reports
- 6.2 Factors critical to quality
- 7.3 Management of CtoQ factors
ICH E8(R1) – see in particular
- 3.2 Critical to quality factors
- 3.3 Approach to identify CtoQ factors
- 5.6 Statistical analysis
- 6.3 Study reporting
ICH E3 – Structure and Content of Clinical Study Reports
ISO 14155:2020 Medical device (access liable to cost) – see in particular annexes
- 8.4 Clinical investigation report
- Annex D Clinical investigational report
- Annex F Adverse event categorization
Swiss Law
ClinO – see in particular article
- Art. 38 Notification upon study completion, discontinuation or interruption
- Art. 43 Reporting on the safety of participants
- Art. 57b Reporting on the safety of participants
- Art. 62d Applicable provisions
ClinO-MD – see in particular article
- Art. 36 Notification of study termination or interruption
- Art. 35 Annual reporting on the safety of participants
- Art. 38 Notification and reporting to Swissmedic
HRO – see in particular articles
- Art. 22, 36 and 40 Notification of study termination or interruption